![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.biospace.com/article/releases/medimetriks-mm36-difamilast-atopic-dermatitis-development-program-streamlined-following-fda-meeting/
https://www.prnewswire.com/news-releases/medimetriks-announces-that-otsuka-achieved-positive-top-line-phase-3-results--for-mm36-difamilast-in-japanese-adult-and-pediatric-atopic-dermatitis-patients-301030094.html
http://www.prnewswire.com/news-releases/medimetriks-pharmaceuticals-inc-submits-a-new-drug-application-to-fda-for-ozenoxacin-cream-1-a-novel-impetigo-treatment-300290327.html
http://www.prnewswire.com/news-releases/otsuka-licenses-pre-phase-3-topical-atopic-dermatitis-treatment-to-medimetriks-300216786.html